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Abstract 
Purpose: Description of the prescribing patterns of gastric acid suppressant treatment in peptic ulcer 
disease and the cost analysis in a tertiary health center in Malaysia 
Methods:  A cross sectional retrospective study was conducted at a Universiti Sans Malaysia (USM) 
Health Center, Clinic, Malaysia. Convenience sampling was used to include 100 peptic ulcer patients.  
Results: Sixty three percent of the patients were male and 37 % female. The majority of the patients 
were Malay (71 %) and mean age was 46 ± 9.7 years. The most frequently prescribed monotherapy 
antiulcer drugs were ranitidine (83 %) and omeprazole (17 %), while for combination therapy (with 
antacids), it was ranitidine (85 %). The average cost of anti-ulcer drug therapy was 15.54 Ringgit 
Malaysian (RM), i.e., (USD 4.98) for omeprazole and RM 4.62 (USD 1.48) for ranitidine.  
Conclusion: The practitioners in this study preferred to prescribe ranitidine much more frequently than 
omeprazole. Considering the cost burden of proton pump inhibitors (PPIs) and their relatively more 
adverse effects, this may be a cost-effective strategy, but the benefits of ranitidine in terms of 
therapeutic efficacy need to be ascertained.  
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Although a majority of studies report a decrease 
in the incidence or prevalence of PUD over time, 
it remains a common condition. The two most 
common causes implicated are Helicobacter 
pylori (H. pylori) and non-steroidal 
antiinflammatory drugs (NSAID) use [1]. Apart 
from therapy for eradication of H. pylori and 
discontinuation of NSAID when indicated, the 
main strategy against peptic ulcer disease (PUD) 
remains gastric acid suppression.  
 
The use of proton pump inhibitors varies 
between gastroenterologists and primary care 
physicians, although most physicians believe that 
proton pump inhibitors are safe, few believe that 
they should be available without a prescription 
[2]. While proton pump inhibitors are undoubtedly 
effective agents, studies of their prescribing 
pattern in practice consistently suggest overuse 
prior to endoscopy, use in patients who do not fit 
the approved criteria, and prescribing for 
indications in which less potent agents should 
have been sufficiently effective for the patient's 
symptoms [3]. Also, PPIs are not completely 
benign medications as there are a lot of 
associated adverse events such as increased 
risk of community acquired pneumonia, 
increased risk of Salmonella and Campylobacter 
infection, delayed diagnosis of gastric cancer and 
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reports of severe hypomagnesaemia resistant to 
magnesium replacement.  
 
For Caucasian patients, PPIs are definitely a 
preferred option among the gastric suppressants 
because of proven efficacy. When treating PUD 
patients of Asian origin, the fact that parietal cell 
mass and acid secretory capacity is much less 
than Caucasians, allows use of much less dose 
with similar response. But in eastern regions the 
prescribing patterns for PUD remains to be 
ascertained.  Preference of H2 receptor blockers 
over proton pump inhibitors (PPIs) in Asian 
patients may not only be justified but also a very 
economical approach, given the much higher 
cost of PPIs as compared to H2 blockers. In an 
economically constrained scenario, pharmaco-
economics of such an approach is very 
appealing as it would mean utilization of any 
savings for other health care demands. 
 
METHODS  
    
Setting  
 
This study was conducted in Universiti Sans 
Malaysia Health Center (USM), Malaysia. USM is 
a primary health centre, catering to the health 
care needs of university staff and their 
dependants. 
 
Study design  
 
A retrospective cross-sectional study was 
conducted, using convenience sampling which 
included the first 100 patients’ files with peptic 
ulcer. The data source of this study was gathered 
from the patients’ record for six months, and 
prescriptions available at the USM health Center 
Clinic, Malaysia. The data collection form mainly 
consisted of demographic data of the patient, 
drug usage, drug cost and patterns of therapy.  
 
Inclusion and exclusion criteria  
 
Adults aged 18 years old and above with 
confirmed peptic ulcer were included. Peptic 
ulcer diagnosis was confirmed clinically, mainly 
by other hospitals via endoscopy. Exclusion 
criteria were patients < 18 years old and non-
confirmed peptic ulcer patients. Prescriptions 
fulfilling our inclusion criteria were selected and 
required information was gathered using our 
collection form. The documentation involved: 
Drug usage (drug name, dose, dosage form, 
frequency, duration and costs), Pattern of 
therapy (mono- or combination) and 





The data was entered into SPSS, version 13.0, 
software and suitable statistical tests were used 
to analyze the data gathered from the data 
collection form. Descriptive analysis was used to 




A total of 100 patients were studied of which 63 
% were male and 37% were female. The majority 
of the patients were Malaya (71 %), Chinese 
were 7%, Indian 12 % and others were 12 %. 
Mean age of the patients was 45.94. Table 1 
gives the mean duration of therapy for each drug 
and the mean cost.  The majority of the patients 
were prescribed ranitidine (83%) as monotherapy 
(Table 2). Omeprazole was prescribed much less 
frequently (17%). Even as combination therapy 
the most frequently prescribed drug was 
ranitidine (85%). The average cost of drug 
therapy of gastric acid suppressant drugs was 
RM 15.54 (USD 4.98) for omeprazole as 
compared to just RM 4.62 (USD 1.48) for 
ranitidine (Table 3). Finally Table 4 gives the 
association of comorbidities with our PUD 
patients. More than half of our patients (52) had 
an associated comorbidity; hypertension and 
dyslipidemia were encountered most frequently. 
Forty eight of our patients did not have an 
associated comorbidity and presented only for 
treatment of PUD (Table 4).  
 
Table 1: Mean duration of therapy (n = 100)  
 
Parameter Mean ± sd 
Duration of omeprazole  (days) 31.24±11.30 
Duration of ranitidine (days) 20.75±12.60 
Duration of Actal (days) 6.33±4.90 
Duration of Zellox (days) 9.13±8.340 
Cost of therapy (RM/day) 6.79±5.79  
(USD 2.18±1.86) 
Number of visits (days) 1.53±1.08 
Zellox® composition: aluminum hydroxide 
magnesium hydroxide simethicone 
Actal® composition: sodium polyhydroxyaluminium 




In the present study, the most frequent antiulcer 
drugs used as monotherapy and combination 
therapy were H2-receptor inhibitors (H2RAs, 83 - 
85 %), PPIs were the less frequently used 
antiulcer drugs as monotherapy as well as in 
combination therapy (17 - 14 %). Thus, in our 
study, H2RAs were much more preferred to 
PPIs. 
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Table 2: Distribution of antiulcer drugs utilized by 
the patients (n=100) 
 
 N % 
Mode of therapy 
Monotherapy 65 65 
Combination therapy          35     35 
 
Most frequent antiulcer drugs as 
monotherapy 
Ranitidine 54 83 
Omeprazole 11 17 
Actal 0 0 
Zellox 0 0 
 
Most frequent antiulcer drugs as 
combination therapy 
Ranitidine +actal 18 51.4 
Ranitidine +zellox 12 34.3 
omeprazole +actal 3 8.6 
omeprazole +zellox 2 5.7 
Zellox® composition: aluminum hydroxide 
magnesium hydroxide simethicone 
Actal® composition: sodium polyhydroxyaluminium 
monocarbonate hexitol complex 
 
 




Average cost drug 






Zellox® composition: aluminum hydroxide magnesium 
hydroxide simethicone 
Actal® composition: sodium polyhydroxyaluminium 
monocarbonate hexitol complex 
 
Gastric acid suppressant therapy in the form of 
an H2 blocker or proton pump inhibitor for four 
weeks induces healing in most duodenal ulcers. 
Proton pump inhibitors provide superior acid 
suppression, healing rates, and symptom relief 
and are recommended as initial therapy for most 
patients. One meta-analysis of randomized 
controlled trials comparing proton pump inhibitors 
with H2 blockers showed earlier pain control and 
better healing rates at four weeks for proton 
pump inhibitors (85 versus 75 %) [4]. Another 
systematic review of randomized controlled trials 
showed that proton pump inhibitors healed 
duodenal ulcers in more than 95 % of patients at 
four weeks and gastric ulcers in 80 to 90 percent 
of patients at eight weeks [5]  . PPIs are more 
effective than H2RA in preventing persistent or 
recurrent bleeding from peptic ulcer, although 
this advantage seems to be more evident in 
patients not having adjunct sclerosis therapy.   
However, proton pump inhibitors are not more 
effective than H2RA for reducing surgery or 
mortality rates [6].  
 
Table 4: Co-morbidities associated with peptic 
ulcer disease (n = 100) 
 
Co-morbidities N % 
8 8 
Hyperlipidemia 7 7 
Hemorrhoids 4 4 
Ischemic heart disease 4 4 
Gout 2 2 
Tendinitis 2 2 
Diabetes 2 2 




Diabetes +Hyperlipidemia 3 3 
Gout+ischemic heart dis. 2 2 






Hypertension + Diabetes 
+gout+ hyperlipidemia. 
2 2 
Peptic Ulcer alone 48 48 
 
Recommendations of the majority of guidelines 
and reviews recommend PPI as first line for 
eradication therapy in PUD. Though the 
superiority of PPIs is proven in Western 
literature, it has not been studied in Asian 
populations. The parietal cell mass of Scottish 
patients with duodenal ulcer has been shown to 
be almost double that of Chinese patients, yet 
peptic ulcer occurs in about 10 % in both 
populations. The gastric acid output following 
maximal stimulation is known to be higher in 
western patients and controls than in their Asian 
counterparts, by as much as 80 %. There are two 
known explanations. First, body weight has been 
shown to be closely related to maximal acid 
output, and body size in Asians is generally less 
than that in Caucasians. However, despite 
correction for body stature, Chinese still showed 
a significantly smaller maximal acid output 
compared with age- and sex-matched. Parietal 
cell counts and maximal acid output in Chinese 
and Scottish patients with duodenal ulcer. 
Another explanation may be related to H. pylori 
gastritis, which is common among Asians and 
which may reduce the acid secretion, especially 
when the body and fundus are involved.  
 
The parietal cell mass is much less in Asians [7]. 
The fact that acid secretion in Asians is only 
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about 60 % of that in Caucasians is of 
importance when treating Asian patients with 
acid-reducing agents [8]. Identical suppression of 
acid secretion  induced by graded doses of 
pentagastrin, has been shown with cimetidine 
100 mg and 200 mg intravenously, in Chinese 
patients with duodenal ulcer, suggesting that half 
the standard dose of cimetidine that is 
recommended for Caucasians might achieve 
adequate acid suppression in Chinese; this has, 
in fact, been reiterated by a double-blind, 
placebo-controlled study showing that cimetidine 
100 mg and 200 mg was as effective as 200 mg 
three times daily and 400 mg for the healing of 
duodenal ulcer[9,10].Thus the preference of 
H2RAs to PPIs in the present study may thus be 
justified keeping in view the difference in acid 
secretion as well as response to gastric acid 
suppressants in Asian population.   
 
Even in Western literature, there is a wide 
variation in amount of PPIs used by the GPs, a 
multifold difference between the highest and 
lowest users. It was found that a significantly 
large percentage of patients were being 
prescribed proton pump inhibitors for the 
unlicensed indications of non-ulcer dyspepsia 
and nonspecific abdominal pain. In 1998, there 
were 2 million prescriptions for proton pump 
inhibitors dispensed throughout Australian 
community pharmacies, at a cost to government 
of approximately Australian $180 million; 
omeprazole was the second most costly 
Pharmaceutical Benefits Scheme item for that 
year. Total PPIs prescribing increased yearly in 
some studies, between 1990 and 1996; while the 
prescription of proton pump inhibitors rapidly 
increased, the use of H2-antagonists did not 
decrease greatly. There is thus a wide variation 
in use of PPIs and a scope for improvement [11]. 
In the west there has been a decline in use of 
H2RAs and a multifold increase in prescriptions 
of PPIs [12].   
 
 Moreover, our study also demonstrates that 
there is a major difference in the cost of therapy 
(The average cost of drug therapy of gastric acid 
suppressant drugs was 15.54 RM(4.98USD) for 
omeprazole as compared to just 4.62 RM(1.48 
USD) for ranitidine). Thus H2RAs have a definite 
advantage over PPIs from economic point of 
view, especially in developing nations. When we 
look at the co-morbidities, we find that more than 
half the patients of PUD have an associated co-
morbidity for which they would require treatment. 
This obviously increases the total cost of the 
prescription and thus it is all the more important 
to look for means for lessening the economic 
burden of disease, like was the case in our study, 
wherein preference of H2RAs meant a definite 
reduction in the total cost. 
 
While the proton pump inhibitors are no doubt 
effective agents , and studies to be imposed on 
the ground indicate consistently excessive use 
before endoscopy, use in patients who do not fit 
the criteria, and description of the indicators that 
agents' less powerful "should be effective, 
including enough to the symptoms of the patient.  
 
Over utilization of proton pump inhibitors without 
an adequate trial of H2-antagonists. The cost-
effectiveness of such changes in prescribing 
remains unclear. Concern has been expressed 
that many patients may be treated with these 
expensive drugs without having tried life-style 
modification or simpler, less expensive 
treatments.   
 
Though PPIs are now among the most 
commonly prescribed medications worldwide, 
they are not entirely innocuous.  A large number 
of patients - as many as 90% in one study [13] - 
are taking these drugs with no appropriate 
guideline-based indications.  This raises fears of 
an economic and safety, particularly in light of 
the suggestion that these drugs may delay the 
diagnosis of gastric cancer [14]. Taking a proton 
pump inhibitor may allow patients to continue an 
unhealthy life-style which may be detrimental for 
their heart as well as their heartburn. Found that 
a significantly large percentage of patients were 
being prescribed proton pump inhibitors for the 
unlicensed indications of non ulcer dyspepsia 
and nonspecific abdominal pain.  Several studies 
have shown that current PPI use, particularly if 
started recently, is associated with an increased 
risk of Community acquired pneumonia[15]. The 
studies did not consistently observe an 
association with H2RAs, perhaps because of 
their weaker acid suppressant activity. One study 
examining cardiothoracic surgery patients taking 
stress ulcer prophylaxis found pantoprazole, but 
not ranitidine, was associated with an increased 
risk of hospital-acquired pneumonia[16] . It has 
been suggested that losing the non-specific 
defense of a gastric pH below 4 results in more 
gut flora residing in the upper gastrointestinal 
tract, and the more powerful acid suppressant 
effects of PPIs would therefore be expected to be 
more strongly linked with pneumonia, as is 
observed.  
 
There is also a significant body of observational 
evidence linking gastric acid suppression to 
enteric infection. A systematic review published 
in 2007[17] reported an increased risk of 
Salmonella and Campylobacter infection in those 
using gastric acid suppressants. The association 
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was greater with PPIs   than H2RAs, but 
remained significant for H2RAs. Gastric acid 
suppression is associated with colonization of the 
normally sterile upper GI tract; acid suppression 
may therefore remove an important physiological 
barrier, allowing orally ingested enteric 
pathogens to reach the gut.  
 
Perhaps most importantly for older people, acid 
suppression may also be associated with an 
increased risk of Clostridium difficile-associated 
disease (CDAD). Although some studies did not 
find an association between PPIs and CDAD, a 
number of other studies have demonstrated that 
PPI use increases the risk of developing CDAD 
in both hospitalised and community-dwelling 
patients, with a meta-analysis reporting a 
significant increase in risk  the association  for 
H2RA use appears to be weaker. Patients 
treated for CDAD are more likely to have a 
recurrence if they remain on PPI therapy [18].  
 
There are other potentially adverse effects of 
gastric acid suppressants that are relevant to the 
health of older people. A number of case reports 
have suggested a relationship between PPIs and 
microscopic colitis, a condition now increasingly 
recognised as a cause of chronic watery 
diarrhoea in older people. Severe 
hypomagnesaemia resistant to magnesium 
replacement but resolving on withdrawal of PPI 
has been reported, especially in older people 
[19]. This can be partially corrected by high-dose 
oral magnesium supplement, suggesting that 
PPIs inhibit the active transport mechanism of 
intestinal magnesium absorption. Low serum 
magnesium levels have been shown to be 
associated with adverse prognosis and increased 
mortality in various settings and have been found 
to independently correlate with muscle 
performance in older people.  
 
The change in gastric acidity with consequent 
changes in drug absorption has been blamed for 
malabsorption of nutrients including iron, vitamin 
B12 and many of the drug interactions with PPIs. 
Although this has not been of major clinical 
concern, the recent controversy surrounding 
concomitant use of PPIs and clopidogrel serves 
as a reminder that this class of drugs is not 
without the risk of interactions. Finally, some 
recent studies have suggested an association 
between PPI use and increased risk of 
osteoporotic fracture, although this association 
does not appear to be consistent across all 
populations.   There is no doubt that gastric acid 
suppressants are important drugs with a crucial 
role in the management of a number of GI 
diseases, and care is needed to ensure that 
patients taking these agents for good indications 
do not have their prescriptions stopped. 
However, there is good evidence that they are 
frequently being prescribed for non-specific and 
inappropriate reasons, and that a large number 
of patients are taking these agents for much 




The majority of patients of PUD in this study 
were on ranitidine, while only few others were 
placed on omeprazole.  Thus, H2RAs were 
clearly the preferred gastric acid suppressants in 
this study population. The rationale for this 
prescribing pattern is probably a reduction in cost 
burden, adverse event profile of PPIs and 
consideration of PPIs for only recurrent cases 
when H2 antagonists fail. What remains to be 
ascertained is the therapeutic effectiveness of 
H2RAs over PPIs in Asian patients with PUD.  
  
Limitations of the study 
 
Study population is limited to only a single centre 
in Penang, Malaysia and looks only into the 
prescribing pattern in PUD. Further prospective 
studies are required to find and compare the 
response of H2blockers and PPIs in PUD in 
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